Skip to main content
Premium Trial:

Request an Annual Quote

Orchid’s Q3 Revenue Slides 4 Percent as Restructuring Helps Cut Loss 65 Percent

NEW YORK (GenomeWeb News) — Orchid Cellmark today said third-quarter revenues decreased 4 percent as R&D spending declined 16 percent and losses fell 65 percent.
 
Total receipts for the three months ended Sept. 30 decreased to $15.7 million from $16.4 million year over year.
 
R&D spending decreased to $316,000 from $376,000 year over year.
 
The company said losses declined to $1.3 million from $3.8 million in the year-ago period.
 
Orchid president and CEO Thomas Bologna said the quarterly improvement in the loss column reflects a “clear improvement” and “indicate[s] that our restructuring initiatives gained substantial traction in the third quarter.”
 
Orchid said it had around $12.5 million in cash and cash equivalents as of Sept. 30.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.